Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | GALR1 | P47211 | 3/20 | 0.45 |
| ▸ | GALR2 | O43603 | 2/20 | 0.45 |
| ▸ | ACP1 | P24666 | 9/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753155 | 0.86 | LMNA (0.45) | MAPTKMT2AACP1SLC6A7 | |
| SCHEMBL1753142 | 0.84 | RAB9A (0.53) | RAB9AMAPTKMT2ANPC1DRD2 | |
| SCHEMBL1752993 | 0.79 | DRD2 (0.48) | RAB9AMAPTKMT2ANPC1DRD2 | |
| Minozac Free Base SCHEMBL1752767 | 0.75 | MAPT (0.48) | RAB9AMAPTKMT2ANPC1DRD2 | |
| SCHEMBL29572108 | 0.74 | SLC6A7 (0.56) | MAPTKMT2ADRD2DRD4DRD3 | |
| SCHEMBL720267 | 0.74 | SLC6A7 (0.56) | MAPTKMT2ADRD2DRD4DRD3 | |
| Minozac Free Base SCHEMBL2799232 | 0.74 | TSHR (0.47) | RAB9AMAPTNPC1DRD2DRD4 | |
| Minozac Free Base SCHEMBL29369390 | 0.74 | TSHR (0.47) | RAB9AMAPTNPC1DRD2DRD4 | |
| SCHEMBL1752911 | 0.73 | HTT (0.51) | RAB9AMAPTKMT2ANPC1DRD2 | |
| Minozac Free Base SCHEMBL2394574 | 0.73 | TSHR (0.46) | RAB9AMAPTNPC1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | U.S. GOVERNMENT (US) | 2012-06-21 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | RAB9A 4206/4885MAPT 27/4885KMT2A 3472/4885 |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | RAB9A 3422/4885MAPT 21/4885KMT2A 1951/4885 |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | RAB9A 3422/4885MAPT 21/4885KMT2A 1951/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | RAB9A 4075/4885MAPT 32/4885KMT2A 3321/4885 |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | RAB9A 4169/4885MAPT 31/4885KMT2A 3504/4885 |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | C5, PNPO, CHRNA5 | RAB9A 2301/4885MAPT 1953/4885KMT2A 2766/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | RAB9A 4206/4885MAPT 27/4885KMT2A 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.